{"title":"Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: A population-based study","authors":"A. H. Rittig, O. Hilberg, A. Løkke","doi":"10.1183/13993003.CONGRESS-2018.PA3659","DOIUrl":null,"url":null,"abstract":"Introduction: Hypersensitivity pneumonitis (HP) is a rare interstitial lung disease (ILD), with an almost undescribed lethality. Very few studies have investigated HP on a national level. Aim: The aim of this study was to investigate incidence, survival rate and comorbidity of this disease nationwide in Denmark. Methods: Using the Danish National Patient Registry we identified all patients with a first-time diagnosis of HP between 1998 and 2010. Patients with HP were matched 1:4 with controls by gender, age, marital status and geography. Co-morbidity three years prior to diagnosis was explored by the Charlson index score. Survival rates were assessed using Kaplan-Meier curves and Hazard Ratios. Results: We identified 753 patients (men: 56.7%) during the observation period and an average HP-incidence of 63 pr. Year. More than half (388 patients = 51.5%) was below 50 years. Survival rates of HP were lower at all time points when compared to the matched control population. The highest mortality among patients with HP was observed during the first two years following initial diagnosis - revealing a higher mortality rate in the age groups 0-39 and 60-80+. Furthermore, patients had a significant higher Charlson index score when compared to the matched controls (0.2 vs 0.008; p Conclusion: For the first time ever, national, longitudinal data regarding age at diagnosis, incidence, hospital contacts, co-morbidity and the mortality rate of HP are presented. We found an increased mortality among HP patients compared with a matched control group without HP. This might indicate, that this rare disease should be centralized to a few centers with high expertise in treatment modalities.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ILD/DPLD of known origin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3659","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Introduction: Hypersensitivity pneumonitis (HP) is a rare interstitial lung disease (ILD), with an almost undescribed lethality. Very few studies have investigated HP on a national level. Aim: The aim of this study was to investigate incidence, survival rate and comorbidity of this disease nationwide in Denmark. Methods: Using the Danish National Patient Registry we identified all patients with a first-time diagnosis of HP between 1998 and 2010. Patients with HP were matched 1:4 with controls by gender, age, marital status and geography. Co-morbidity three years prior to diagnosis was explored by the Charlson index score. Survival rates were assessed using Kaplan-Meier curves and Hazard Ratios. Results: We identified 753 patients (men: 56.7%) during the observation period and an average HP-incidence of 63 pr. Year. More than half (388 patients = 51.5%) was below 50 years. Survival rates of HP were lower at all time points when compared to the matched control population. The highest mortality among patients with HP was observed during the first two years following initial diagnosis - revealing a higher mortality rate in the age groups 0-39 and 60-80+. Furthermore, patients had a significant higher Charlson index score when compared to the matched controls (0.2 vs 0.008; p Conclusion: For the first time ever, national, longitudinal data regarding age at diagnosis, incidence, hospital contacts, co-morbidity and the mortality rate of HP are presented. We found an increased mortality among HP patients compared with a matched control group without HP. This might indicate, that this rare disease should be centralized to a few centers with high expertise in treatment modalities.
简介:过敏性肺炎(HP)是一种罕见的间质性肺疾病(ILD),其致死率几乎未被描述。很少有研究在国家层面上调查HP。目的:本研究的目的是调查丹麦全国本病的发病率、生存率和合并症。方法:使用丹麦国家患者登记处,我们确定了1998年至2010年间首次诊断为HP的所有患者。HP患者按性别、年龄、婚姻状况和地理位置与对照组1:4匹配。通过Charlson指数评分探讨诊断前3年的合并症。生存率采用Kaplan-Meier曲线和风险比进行评估。结果:在观察期间,我们确定了753例患者(男性:56.7%),平均hp发病率为63 /年。超过一半(388例= 51.5%)的患者年龄在50岁以下。与匹配的对照人群相比,HP的存活率在所有时间点都较低。HP患者在最初诊断后的头两年死亡率最高,这表明0-39岁和60-80岁以上年龄组的死亡率更高。此外,与匹配的对照组相比,患者的Charlson指数评分显著更高(0.2 vs 0.008;p结论:有史以来第一次提出了关于HP的诊断年龄、发病率、医院接触、合并症和死亡率的全国纵向数据。我们发现与没有HP的对照组相比,HP患者的死亡率增加。这可能表明,这种罕见的疾病应该集中在少数具有高专业知识的治疗方式的中心。